阮洋 周軼冰 周東航
摘要:目的? 探討FSTL1和TNF-α在糖尿病合并胃癌發(fā)生發(fā)展中的作用,以期為臨床治療該病提供新的思路和作用靶點(diǎn)。方法? 選取2016年1月~2019年12月我院經(jīng)手術(shù)治療且資料完整的50例無(wú)糖尿病胃癌患者(單純胃癌組)和50例糖尿病合并胃癌患者(糖尿病合并胃癌組)作為研究對(duì)象,檢測(cè)兩組患者癌組織中FSTL和TNF-α的表達(dá)情況,分析FSTL和TNF-α與糖尿病合并胃癌患者臨床病理學(xué)特征(年齡、性別、腫瘤大小、病理分期、分化程度、淋巴結(jié)轉(zhuǎn)移情況)的關(guān)系。結(jié)果? ①糖尿病合并胃癌組FSTL1表達(dá)低于單純性胃癌組,TNF-α表達(dá)高于單純性胃癌組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);②糖尿病合并胃癌患者中,不同年齡、性別的患者FSTL1 和 TNF-α表達(dá)比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P>0.05);不同腫瘤大小、病理分期、分化程度、淋巴結(jié)轉(zhuǎn)移情況的患者FSTL1 和TNF-α表達(dá)比較,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);③糖尿病合并胃癌患者癌組織中FSTL1與TNF-α的表達(dá)呈負(fù)相關(guān)(rs=-0.4155,P<0.05)。結(jié)論? FSTL1和TNF-α與糖尿病合并胃癌患者癌組織的生長(zhǎng)、增殖、分化和轉(zhuǎn)移具有相關(guān)性,它們可能在糖尿病合并胃癌的發(fā)生發(fā)展中發(fā)揮著重要作用,且FSTL1與TNF-α的表達(dá)呈負(fù)相關(guān)。
關(guān)鍵詞:FSTL1;TNF-α;糖尿病;胃癌
Abstract:Objective? To explore the role of FSTL1 and TNF-α in the occurrence and development of diabetes mellitus complicated with gastric cancer, in order to provide new ideas and targets for clinical treatment of the disease.Methods? From January 2016 to December 2019, 50 patients with diabetes-free gastric cancer (simple gastric cancer group) and 50 patients with diabetes mellitus and gastric cancer (diabetes mellitus combined with gastric cancer group) who had undergone surgical treatment and complete data were selected as the research objects. The expression of FSTL and TNF-α in cancer tissues of patients in the group, and the relationship between FSTL and TNF-α and clinicopathological characteristics (age, gender, tumor size, pathological stage, degree of differentiation, lymph node metastasis) in patients with diabetes mellitus and gastric cancer were analyzed. Results? ①The expression of FSTL1 in the diabetes mellitus combined with gastric cancer group was lower than that in the simple gastric cancer group, and the expression of TNF-α was higher than that in the simple gastric cancer group,the difference was statistically significant (P<0.05);②The expressions of FSTL1 and TNF-α in patients with diabetes mellitus and gastric cancer of different ages and genders were not statistically different (P>0.05); The expression of FSTL1 and TNF-α in patients with different tumor size, pathological stage, degree of differentiation, and lymph node metastasis were compared,the difference was statistically significant (P<0.05); ③The expression of FSTL1 and TNF-α in cancer tissues of patients with diabetes mellitus and gastric cancer was negative correlation (rs=-0.4155,P<0.05).Conclusion? FSTL1 and TNF-α were related to the growth, proliferation, differentiation and metastasis of cancer tissues in patients with diabetes mellitus and gastric cancer. They might play an important role in the occurrence and development of diabetes mellitus and gastric cancer, and the expression of FSTL1 and TNF-α was negative related.
[13]Zhou X,Xiao X,Huang T,et al.Epigenetic inactivation of follistatin-like 1 mediatestumorimmune evasion in nasopharyngeal carcinoma[J].Oncotarget,2016,7(13):16433-16444.
[14]Bae K,Park KE,Han J,et al.Mitotic cell death caused by follistatin-like 1 inhibitionis associated with up-regulated Bim by inactivated Erk1/2 in human lung cancer cells[J].Oncotarget,2016,7(14):18076-18084.
[15]Gold E,Risbridger G.Activins and activin antagonists in the prostate and prostate cancer[J].Mol Cell Endocrinol,2012,359(1-2):107-112.
[16]Kudo-Saito C,F(xiàn)uwa T,Murakami K,et al.Targeting FSTL1 prevents tumor bonemetastasis and consequent immunedysfunction[J].Cancer Res,2013,73(20):6185-6193.
[17]Wang H,Wu S,Huang S,et al.Follistatin-like protein 1 contributes to dendritic cell and T-lymphocyte activation in nasopharyngeal carcinoma patients by altering nuclear factor κb and Jun N-terminal kinase expression[J].Cell Biochem Funct,2016,34(8):554-562.
[18]American Diabetes Association(ADA)2015 Guidelines: Cardiovascular Disease Risk Management for Diabetes[J].Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease,2015(2):37.
[19]梁懿璣.2型糖尿病血糖與炎癥因子相關(guān)性分析[J]. 實(shí)用婦科內(nèi)分泌雜志(電子版),2017,4(27):83-86.
[20]鄭山.tmTNF-α在胰島素抵抗中的作用及其機(jī)制[D].華中科技大學(xué),2015.
[21]刁卓,劉曉超,唐玉虎,等.RIP3及TNF-α在胃癌組織中的表達(dá)及臨床意義[J].現(xiàn)代腫瘤醫(yī)學(xué),2017,25(14):2283-2287.
[22]Pao W,Chmielecki J.Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer[J].Nat Rev Cancer,2010,10(11):760-774.
收稿日期:2020-05-23;修回日期:2020-06-06
編輯/成森